Case Study Downloads
“Successfully filing an IND using Solentim’s VIPS™ single cell cloning system”
Biotheus Inc. was granted an IND in March 2020 for its bispecific therapeutic asset, PM8001. Regulatory approval was attained with help from the Solentim VIPS™ system for single cell cloning and clonality reporting.
In this short case study, Dr Andy Tsun, Co-Founder and VP of Discovery Biology at Biotheus Inc, shares his company’s experience using the VIPS, including how it helped accelerate their cell line development process and crucially satisfy the regulatory requirements.
“FACS bulk enrichment combined with the VIPS and Cell Metric delivered significant savings for a CDMO”
In this case study, Celonic AG showed the impact of switching from their original minipools/limiting dilutions workflow to one which combined FACS + VIPS. Although FACS was useful for enrichment, it damaged their CHO cell line for single cell seeding resulting in poor survival and outgrowth. By implementing the VIPS for gentle single cell cloning combined with cloning media optimisation, outgrowth improved from around 5% with FACS to over 60% using the VIPS. Read the details of these changes and how they benefited the customer by reducing the number of cloning plates per project by up to 25-fold.
“Doubling the Speed of Cell Line Development in a Large Pharmaceutical Company”
Using Solentim’s VIPS technology, Janssen Pharmaceuticals has halved cell line development (CLD) workflow times whilst still meeting proof of clonality requirements for regulators. Download the case study now to find out the many benefits of the VIPS System, including the combination with ATUM’s transposases, and to discover how this approach to single cell cloning is revolutionising Janssen’s CLD workflow.
“Cutting Cell Line Development Timelines from 6 months to Less Than 13 weeks”
By transitioning to use a combination of Solentim’s VIPS and Cell Metric CLD products, as opposed to the previously used ClonePix (picking from semi-solid media) technology, Genmab significantly slashed workflow times over competing single cell cloning methods. Learn more about the practical benefits that this has already delivered for the company and the motivations behind Genmab’s technology shift.
“Reducing the Timeline by 30% to Produce a Monoclonal Cell Line Expressing a Clinical Candidate Bi-Specific Antibody”
SystImmune’s chosen path forward to proof of clonality was to introduce the Solentim Cell Metric CLD into their cell line development process. The Cell Metric cell imaging system can image the entire well and provide a sharp image of a single cell on Day 0 which is critical proof of a single cell and will allow for a single round of cloning.